EnteroBiotix has completed enrolment in a Phase 2a clinical trial (called MAST). The trial is testing EBX-102-02, a microbiome-based therapy. It includes 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). Patients receive either EBX-102-02 or a placebo before chemotherapy and transplant; They are followed for 12 months after transplant.
The goal is to see whether restoring the gut microbiome can Improve overall survival, Maintain microbial diversity, Reduce complications like infections or graft-versus-host disease (GVHD). During stem cell transplants the gut microbiome is severely disrupted and lower diversity is strongly linked to worse outcomes and higher mortality. This trial is testing a preventive (pre-emptive) approach—intervening before damage occurs, which is a big strategic shift.
The trial which is sponsored by Imperial College London Funded by Medical Research Council is now fully enrolled with topline results expected: H1 2027.